

EXPONENT INC  
Form 10-Q  
May 03, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 29, 2019

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 0-18655

**EXPONENT, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

**77-0218904**

(State or other jurisdiction of (I.R.S. Employer Identification No.)  
incorporation or organization)

**149 COMMONWEALTH DRIVE, MENLO PARK, CALIFORNIA 94025**

(Address of principal executive office)

(Zip Code)

**(650) 326-9400**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	EXPO	Nasdaq Global Select Market

As of April 26, 2019, the latest practicable date, the registrant had 51,901,032 shares of common stock outstanding.

EXPONENT, INC.

FORM 10-Q

TABLE OF CONTENTS

	<b>Page</b>
 <b><u>PART I – FINANCIAL INFORMATION</u></b>	
<b><u>Item 1. Financial Statements (unaudited):</u></b>	
<u>Condensed Consolidated Balance Sheets March 29, 2019 and December 28, 2018</u>	<u>3</u>
<u>Condensed Consolidated Statements of Income Three Months Ended March 29, 2019 and March 30, 2018</u>	<u>4</u>
<u>Condensed Consolidated Statements of Comprehensive Income Three Months Ended March 29, 2019 and March 30, 2018</u>	<u>5</u>
<u>Condensed Consolidated Statements of Stockholders' Equity Three Months Ended March 29, 2019 and March 30, 2018</u>	<u>6</u>
<u>Condensed Consolidated Statements of Cash Flows Three Months Ended March 29, 2019 and March 30, 2018</u>	<u>7</u>
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	<u>8</u>
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	<u>20</u>
<b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	<u>26</u>
<b><u>Item 4. Controls and Procedures</u></b>	<u>26</u>
 <b><u>PART II – OTHER INFORMATION</u></b>	
<b><u>Item 1. Legal Proceedings</u></b>	<u>27</u>
<b><u>Item 1A. Risk Factors</u></b>	<u>27</u>
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	<u>32</u>

<u>Item 3. Defaults Upon Senior Securities</u>	<u>32</u>
<u>Item 4. Mine Safety Disclosures</u>	<u>32</u>
<u>Item 5. Other Information</u>	<u>32</u>
<u>Item 6. Exhibits</u>	<u>33</u>
<u>Signatures</u>	<u>34</u>

## PART I – FINANCIAL INFORMATION

## Item 1. Financial Statements

## EXPONENT, INC.

## Condensed Consolidated Balance Sheets

March 29, 2019 and December 28, 2018

(in thousands, except par value)

(unaudited)

	March 29, 2019	December 28, 2018
Assets		
Current assets:		
Cash and cash equivalents	\$79,080	\$ 127,059
Short-term investments	92,680	81,495
Accounts receivable, net of allowance for contract losses and doubtful accounts of \$4,713 and \$4,066 at March 29, 2019 and December 28, 2018, respectively	118,864	105,814
Prepaid expenses and other current assets	13,986	12,244
Total current assets	304,610	326,612
Property, equipment and leasehold improvements, net	50,854	46,103
Operating lease right-of-use assets	23,852	-
Goodwill	8,607	8,607
Deferred income taxes	33,878	34,090
Deferred compensation plan assets	66,395	52,286
Other assets	1,024	1,238
Total assets	\$489,220	\$ 468,936
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	\$12,377	\$ 12,283
Accrued payroll and employee benefits	46,406	76,855
Deferred revenues	7,567	9,166
Operating lease liabilities	5,843	-

Edgar Filing: EXPONENT INC - Form 10-Q

Total current liabilities	72,193	98,304
Other liabilities	2,702	2,548
Deferred compensation plan liabilities	66,670	52,708
Deferred rent	-	1,467
Operating lease liabilities	18,478	-
Total liabilities	160,043	155,027
Stockholders' equity:		
Common stock, \$0.001 par value; 120,000 shares authorized; 65,707 shares issued at March 29, 2019 and December 28, 2018	66	66
Additional paid-in capital	238,916	227,283
Accumulated other comprehensive income (loss)		
Investment securities, available-for-sale	109	(45 )
Foreign currency translation adjustments	(2,691 )	(2,808 )
	(2,582 )	(2,853 )
Retained earnings	350,506	342,024
Treasury stock, at cost; 13,806 and 14,208 shares held at March 29, 2019 and December 28, 2018, respectively	(257,729)	(252,611 )
Total stockholders' equity	329,177	313,909
Total liabilities and stockholders' equity	\$489,220	\$ 468,936

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

**EXPONENT, INC.**

Condensed Consolidated Statements of Income

For the Three Months Ended March 29, 2019 and March 30, 2018

**(in thousands, except per share data)**

**(unaudited)**

	Three Months Ended	
	<b>March 29, 2019</b>	<b>March 30, 2018</b>
Revenues:		
Revenues before reimbursements	\$ 93,401	\$ 90,684
Reimbursements	5,630	5,773
Revenues	99,031	96,457
Operating expenses:		
Compensation and related expenses	65,093	57,579
Other operating expenses	8,008	7,465
Reimbursable expenses	5,630	5,773
General and administrative expenses	4,546	4,042
Total operating expenses	83,277	74,859
Operating income	15,754	21,598
Other income, net:		
Interest income, net	1,055	530
Miscellaneous income, net	6,513	322
Total other income, net	7,568	852
Income before income taxes	23,322	22,450
Income taxes	610	2,110



Edgar Filing: EXPONENT INC - Form 10-Q

Net income	\$ 22,712	\$ 20,340
Net income per share:		
Basic	\$ 0.43	\$ 0.39
Diluted	\$ 0.42	\$ 0.38
Shares used in per share computations:		
Basic	52,536	52,744
Diluted	53,814	54,012
Cash dividends declared per common share	\$ 0.16	\$ 0.13

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements

- 4 -

EXPONENT, INC.

**Condensed Consolidated Statements of Comprehensive Income**

For the Three Months Ended March 29, 2019 and March 30, 2018

**(in thousands)**

**(unaudited)**

	Three Months Ended	
	<b>March 29, 2019</b>	<b>March 30, 2018</b>
Net income	\$ 22,712	\$ 20,340
Other comprehensive income (loss):		
Foreign currency translation adjustments, net of tax	117	739
Unrealized gains (losses) on available-for-sale investment securities arising during the period, net of tax	154	(40 )
Comprehensive income	\$ 22,983	\$ 21,039

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements

EXPONENT, INC.

**Condensed Consolidated Statements of Stockholders' Equity****(in thousands)****(unaudited)**

(In thousands)	Three Months Ended March 29, 2019							
	Common Stock Shares	Amount	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings	Treasury Stock Shares	Amount	Total
Balance at December 28, 2018	65,707	\$ 66	\$ 227,283	\$ (2,853)	) \$ 342,024	14,208	\$(252,611)	\$ 313,909
Employee stock purchase plan	-	-	302	-	-	(7)	) 70	372
Amortization of unrecognized stock-based compensation	-	-	3,663	-	-	-	-	3,663
Foreign currency translation adjustments	-	-	-	117	-	-	-	117
Grant of restricted stock units to settle accrued bonus	-	-	7,947	-	-	-	-	7,947
Settlement of restricted stock units	-	-	(860)	-	(5,146)	(395)	) (5,188)	(11,194)
Unrealized gain on investments	-	-	-	154	-	-	-	154
Dividends and dividend equivalent rights	-	-	581	-	(9,084)	-	-	(8,503)
Net income	-	-	-	-	22,712	-	-	22,712
Balance at March 29, 2019	65,707	\$ 66	\$ 238,916	\$ (2,582)	) \$ 350,506	13,806	\$(257,729)	\$ 329,177

(In thousands)	Three Months Ended March 30, 2018							
	Common Stock Shares	Amount	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings	Treasury Stock Shares	Amount	Total
	65,707	\$ 66	\$ 210,230	\$ (2,029)	) \$ 303,990	14,169	\$(223,169)	\$ 289,088

Edgar Filing: EXPONENT INC - Form 10-Q

Balance at December 29, 2017											
Employee stock purchase plan	-	-	230	-	-	(8	)	80	310		
Amortization of unrecognized stock-based compensation	-	-	4,057	-	-	-	-	-	4,057		
Foreign currency translation adjustments	-	-	-	739	-	-	-	-	739		
Grant of restricted stock units to settle accrued bonus	-	-	7,643	-	-	-	-	-	7,643		
Settlement of restricted stock units	-	-	(806	)	-	(5,892	)	(463	) (1,939	) (8,637	)
Unrealized gain on investments	-	-	-	(40	)	-	-	-	-	(40	)
Dividends and dividend equivalent rights	-	-	585	-	(7,460	)	-	-	-	(6,875	)
Net income	-	-	-	-	20,340	-	-	-	20,340		
Balance at March 30, 2018	65,707	\$ 66	\$ 221,939	\$ (1,330	)	\$ 310,978	13,698	\$ (225,028)	\$ 306,625		

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

**EXPONENT, INC.**

## Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 29, 2019 and March 30, 2018

**(in thousands)****(unaudited)**

	Three Months Ended	
	<b>March 29, 2019</b>	<b>March 30, 2018</b>
Cash flows from operating activities:		
Net income	\$22,712	\$ 20,340
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation and amortization of property, equipment and leasehold improvements	1,590	1,555
Amortization of premiums and accretion of discounts on short-term investments	(132 )	-
Deferred rent	-	(74 )
Provision for contract losses and doubtful accounts	788	561
Stock-based compensation	5,731	6,289
Deferred income tax provision	161	(815 )
Changes in operating assets and liabilities:		
Accounts receivable	(13,838 )	(7,700 )
Prepaid expenses and other current assets	(10,431 )	(5,520 )
Change in operating leases	(425 )	-
Accounts payable and accrued liabilities	(333 )	1,829
Accrued payroll and employee benefits	(16,477 )	(12,383 )
Deferred revenues	(1,599 )	(390 )
Net cash (used in) provided by operating activities	(12,253 )	3,692
Cash flows from investing activities:		
Capital expenditures	(5,670 )	(6,810 )
Purchase of short-term investments	(23,848 )	(11,934 )
Maturity of short-term investments	13,000	8,000
Net cash used in investing activities	(16,518 )	(10,744 )
Cash flows from financing activities:		
Payroll taxes for restricted stock units	(11,194 )	(8,637 )

Edgar Filing: EXPONENT INC - Form 10-Q

Exercise of stock-based payment awards	372	310
Dividends and dividend equivalents rights	(8,593 )	(6,959 )
Net cash used in financing activities	(19,415 )	(15,286 )
Effect of foreign currency exchange rates on cash and cash equivalents	207	696
Net decrease in cash and cash equivalents	(47,979 )	(21,642 )
Cash and cash equivalents at beginning of period	127,059	124,794
Cash and cash equivalents at end of period	\$79,080	\$ 103,152

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 7 -

**EXPONENT, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1: Basis of Presentation**

Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three months ended March 29, 2019 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2018, which was filed with the U.S. Securities and Exchange Commission on February 22, 2019.

The unaudited condensed consolidated financial statements include the accounts of Exponent, Inc. and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

**Stock Split.** On May 31, 2018, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to (i) increase the number of authorized shares of common stock to 120,000,000 and (ii) effect a two-for-one stock split. As a result of the stock split, each shareholder of record at the close of business on May 31, 2018, received one additional share of common stock for each share of common stock owned by such shareholder. Restricted stock unit awards and stock option awards have also been adjusted to reflect the two-for-one stock split. For periods prior to the stock split, all share and per share data in the Company’s condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the stock split.

**Dividend.** The Company declared and paid cash dividends per common share during the periods presented as follows:

Fiscal Year 2019		
Dividend Amount		
	Per Share	(in thousands)
First Quarter	\$ 0.16	\$ 8,240
Total	\$ 0.16	\$ 8,240

Fiscal Year 2018		
Dividend Amount		
	Per Share	(in thousands)
First Quarter	\$ 0.13	\$ 6,700
Second Quarter	0.13	6,764
Third Quarter	0.13	6,765
Fourth Quarter	0.13	6,723
Total	\$ 0.52	\$ 26,952

On April 18, 2019, the Company's Board of Directors announced a cash dividend of \$0.16 per share of the Company's common stock, payable June 21, 2019 to stockholders of record as of June 7, 2019. The Company expects to continue paying quarterly dividends in the future, subject to declaration by the Company's Board of Directors.



Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates.

**Recently Adopted Accounting Pronouncements.** In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.

The Company adopted the ASU as of the beginning of its first quarter of fiscal 2019. A modified retrospective transition approach is required, requiring the application of the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on December 29, 2018 using the effective date as the date of initial application. Consequently, financial information was not updated and the disclosures required under the new standard were not provided for dates and periods before December 29, 2018.

The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits it not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs. The Company elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease for all asset classes. The Company also elected to apply the short-term lease exception for all leases. Under the short-term lease exception, the Company will not recognize ROU assets or lease liabilities for leases that, at the acquisition date, have a remaining lease term of 12 months or less.

The ASU had a material impact to the Company’s condensed consolidated balance sheet, but did not have an impact on its condensed consolidated statement of income. The most significant impact was the recognition of ROU assets and lease liabilities for its operating leases.

## Note 2: Revenue Recognition

Substantially all of the Company's engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity's performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided), the entity may recognize revenue in the amount to which the entity has a right to invoice. During the first quarter of fiscal 2019, the Company recognized revenue of \$83,397,000 associated with time and materials contracts. These revenues represent 84% of the Company's consolidated revenues and include revenues of \$65,379,000 for the Company's Engineering and Other Scientific segment and \$18,018,000 for the Company's Environmental and Health segment. During the first quarter of fiscal 2018, the Company recognized revenue of \$83,171,000 associated with time and materials contracts. These revenues represent 86% of the Company's consolidated revenues and include revenues of \$64,557,000 for the Company's Engineering and Other Scientific segment and \$18,614,000 for the Company's Environmental and Health segment. The Company's time and materials contracts are terminable and subject to postponement or delay at any time by our clients, and as such, the performance obligations for all of the Company's time and materials contracts have an original expected duration of one year or less.

For fixed-price contracts the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company's rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company's estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides and the following additional considerations:

- the Company considers labor hours at standard rates and expenses to be incurred when pricing its contracts;
  - the Company generally does not incur set up costs on its contracts;
- the Company does not believe that there are reliable milestones to measure progress towards completion;
  - the customer is required to pay the Company for time at standard rates plus materials incurred to date if the contract is terminated early;
- the Company's contracts do not include award fees or bonuses;
- the Company does not include revenue for unpriced change orders until the customer agrees with the changes;
  - historically the Company has not had significant accounts receivable write-offs or cost overruns; and

the Company's contracts are typically progress billed on a monthly basis.

During the first quarter of fiscal 2019 the Company recognized revenue of \$15,634,000 associated with fixed-price contracts. These revenues represent 16% of the Company's consolidated revenues and include revenues of \$14,875,000 for the Company's Engineering and Other Scientific segment and \$759,000 for the Company's Environmental and Health segment. During the first quarter of fiscal 2018 the Company recognized revenue of \$13,286,000 associated with fixed-price contracts. These revenues represent 14% of the Company's consolidated revenues and include revenues of \$12,446,000 for the Company's Engineering and Other Scientific segment and \$840,000 for the Company's Environmental and Health segment. The Company's fixed-price contracts are terminable and subject to postponement or delay at any time by our clients, and as such, the performance obligations for all of the Company's fixed-price contracts have an original expected duration of one year or less.

Deferred revenues represent amounts billed to clients in advance of services provided. During the first quarter of fiscal 2019, \$3,411,000 of revenues were recognized that were included in the deferred revenue balance at December 28, 2018.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were \$4.2 million during the first quarter of fiscal 2019. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were \$10.2 million during the first quarter of fiscal 2018.

**Note 3: Fair Value Measurements**

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including available-for-sale fixed income securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three months ended March 29, 2019 and March 30, 2018. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at March 29, 2019:

(In thousands)	Fair Value Measurements at Reporting Date Using			
	Total	Quoted Prices in Active Markets for Identical Assets	Significant Other Observable Inputs	Significant Unobservable Inputs
		(Level 1)	(Level 2)	(Level 3)
Assets				
Money market securities <sup>(1)</sup>	\$ 770	\$ 770	\$ -	\$ -
Fixed income available-for-sale securities <sup>(2)</sup>	92,680	-	92,680	-
Fixed income trading securities held in deferred compensation plan <sup>(3)</sup>	25,504	25,504	-	-
Equity trading securities held in deferred compensation plan <sup>(3)</sup>	46,240	46,240	-	-
Total	\$ 165,194	\$ 72,514	\$ 92,680	\$ -
Liabilities				
Deferred compensation plan <sup>(4)</sup>	73,119	73,119	-	-
Total	\$ 73,119	\$ 73,119	\$ -	\$ -

(1) Included in cash and cash equivalents on the Company's unaudited condensed consolidated balance sheet.

(2) Included in short-term investments on the Company's unaudited condensed consolidated balance sheet.

(3) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company's unaudited condensed consolidated balance sheet.

(4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company's unaudited condensed consolidated balance sheet.



The fair value of these certain financial assets and liabilities was determined using the following inputs at December 28, 2018:

	Fair Value Measurements at Reporting Date Using			
	Total	Quoted Prices in Active Markets for Identical Assets  (Level 1)	Significant Other Observable Inputs  (Level 2)	Significant Unobservable Inputs  (Level 3)
<b>Assets</b>				
Money market securities <sup>(1)</sup>	\$ 6,213	\$ 6,213	\$ -	\$ -
Fixed income available for sale securities <sup>(2)</sup>	81,495	-	81,495	-
Fixed income trading securities held in deferred compensation plan <sup>(3)</sup>	18,618	18,618	-	-
Equity trading securities held in deferred compensation plan <sup>(3)</sup>	39,160	39,160	-	-
Total	\$ 145,486	\$ 63,991	\$ 81,495	\$ -
<b>Liabilities</b>				
Deferred compensation plan <sup>(4)</sup>	59,349	59,349	-	-
Total	\$ 59,349	\$ 59,349	\$ -	\$ -

(1) Included in cash and cash equivalents on the Company's unaudited condensed consolidated balance sheet.

(2) Included in short-term investments on the Company's unaudited condensed consolidated balance sheet.

(3) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company's unaudited condensed consolidated balance sheet.

(4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company's unaudited condensed consolidated balance sheet.

Fixed income available-for-sale securities as of March 29, 2019 and December 28, 2018 represent obligations of the United States Treasury and other United States agencies. Fixed income and equity trading securities represent mutual funds held in the Company's deferred compensation plan. See Note 7 for additional information about the Company's deferred compensation plan.

Cash, cash equivalents and short-term investments consisted of the following as of March 29, 2019:

(In thousands)	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
Classified as current assets:				
Cash	\$ 73,310	\$ -	\$ -	\$ 73,310
Cash equivalents:				
Money market securities	770	-	-	770
U.S. Treasury securities	5,000	-	-	5,000
Total cash equivalents	5,770	-	-	5,770
Total cash and cash equivalents	79,080	-	-	79,080
Short-term investments:				
U.S. Treasury and agency securities	92,613	174	(107 )	92,680
Total short-term investments	92,613	174	(107 )	92,680
Total cash, cash equivalents and short-term investments	\$ 171,693	\$ 174	\$ (107 )	\$ 171,760

Cash, cash equivalents and short-term investments consisted of the following as of December 28, 2018:

(In thousands)	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value
Classified as current assets:				
Cash	\$ 120,846	\$ -	\$ -	\$ 120,846
Cash equivalents:				
Money market securities	6,213	-	-	6,213
Total cash equivalents	6,213	-	-	6,213
Total cash and cash equivalents	127,059	-	-	127,059
Short-term investments:				
U.S. Treasury and agency securities	81,634	91	(230 )	81,495
Total short-term investments	81,634	91	(230 )	81,495
Total cash, cash equivalents and short-term investments	\$ 208,693	\$ 91	\$ (230 )	\$ 208,554

The following table summarizes the cost and estimated fair value of short-term fixed income securities classified as short-term investments based on stated effective maturities as of March 29, 2019:

(In thousands)	Amortized Cost	Estimated Fair Value
Due within one year	\$ 46,919	\$ 46,815
Due between one and two years	45,694	45,865
Total	\$ 92,613	\$ 92,680

At March 29, 2019 and December 28, 2018, the Company did not have any assets or liabilities valued using significant unobservable inputs.

The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at March 29, 2019 and December 28, 2018, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at March 29, 2019 and December 28, 2018 approximates their carrying value as reported on the Company's unaudited condensed consolidated balance sheet.

There were no other-than-temporary impairments or credit losses related to available-for-sale securities during the three months ended March 29, 2019 and March 30, 2018.

#### **Note 4: Net Income Per Share**

Basic per share amounts are computed using the weighted-average number of common shares outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of common shares outstanding during the period and, when dilutive, the weighted-average number of potential common shares from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.

The following schedule reconciles the shares used to calculate basic and diluted net income per share:



Edgar Filing: EXPONENT INC - Form 10-Q

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Shares used in basic per share computation	52,536	52,744
Effect of dilutive common stock options outstanding	455	322
Effect of dilutive restricted stock units outstanding	823	946
Shares used in diluted per share computation	53,814	54,012

Common stock options to purchase 24,176 shares were excluded from the diluted per share calculation for the three months ended March 29, 2019 due to their antidilutive effect. The weighted-average exercise price for the antidilutive shares was \$54.95 for the three months ended March 29, 2019. There were no options excluded from the diluted per share calculations for the three months ended March 30, 2018.

#### Note 5: Stock-Based Compensation

##### Restricted Stock Units

Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company's stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company's common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who receives a fully vested restricted stock unit award is also granted a matching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company's common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will continue to vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.

The value of these restricted stock unit awards is determined based on the market price of the Company's common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of \$2,068,000 and \$2,232,000 during the three months ended March 29, 2019 and March 30, 2018, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of \$3,530,000 and \$3,508,000 during the three months ended March 29, 2019 and March 30, 2018, respectively.

### Stock Options

Stock options are granted for terms of ten years and generally vest 25% per year over a four-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company grants options at exercise prices equal to the fair value of the Company's common stock on the date of grant. The Company recorded stock-based compensation expense associated with stock option grants of \$133,000 and \$549,000 during the three months ended March 29, 2019 and March 30, 2018, respectively.

The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.

The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company's common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders' dividend equivalent rights.

The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.

**Note 6: Treasury Stock**

On October 19, 2016, the Company's Board of Directors announced \$35,000,000 for the repurchase of shares of the Company's common stock. On January 31, 2019, the Company's Board of Directors announced an additional \$75,000,000 for the repurchase of shares of the Company's common stock.

- 15 -

The Company did not repurchase any shares of its common stock during the three months ended March 29, 2019 and March 30, 2018. As of March 29, 2019, the Company had remaining authorization under its stock repurchase plans of \$92,462,000 to repurchase shares of common stock.

#### Note 7: Deferred Compensation Plans

The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company's creditors. As of March 29, 2019 and December 28, 2018, the invested amounts under the plans totaled \$71,744,000 and \$57,778,000, respectively, and are recorded in prepaid expenses and other current assets and deferred compensation plan assets on the Company's unaudited condensed consolidated balance sheet. These assets are classified as trading securities and are recorded at fair value with changes recorded as adjustments to miscellaneous income, net.

As of March 29, 2019 and December 28, 2018, vested amounts due under the plans totaled \$73,119,000 and \$59,349,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation plan liabilities on the Company's unaudited condensed consolidated balance sheet. Changes in the liability are recorded as adjustments to compensation expense. During the three months ended March 29, 2019 and March 30, 2018, the Company recognized compensation expense of \$5,869,000 and (\$305,000), respectively, as a result of changes in the market value of the trust assets with the same amount being recorded as income in miscellaneous income, net.

#### Note 8: Supplemental Cash Flow Information

The following is supplemental disclosure of cash flow information:

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Cash paid during period:		
Income taxes	\$ 440	\$ 678

Non-cash investing and financing activities:

Unrealized gain (loss) on short-term investments	\$ 154	\$ (40 )
Vested stock unit awards issued to settle accrued bonuses	\$ 7,947	\$ 7,643
Accrual for capital expenditures	\$ 1,903	\$ 299
Right-of-use asset obtained in exchange for operating lease obligations	\$ 25,653	\$ -

## Note 9: Accounts Receivable, Net

At March 29, 2019 and December 28, 2018, accounts receivable, net, was comprised of the following:

(In thousands)	March 29, 2019	December 28, 2018
Billed accounts receivable	\$ 78,814	\$ 73,905
Unbilled accounts receivable	44,763	35,975
Allowance for contract losses and doubtful accounts	(4,713 )	(4,066 )
Total accounts receivable, net	\$ 118,864	\$ 105,814

On January 29<sup>th</sup> 2019, PG&E Corp. (“PG&E”) filed for bankruptcy under chapter 11 of the U.S. bankruptcy code. The Company’s total outstanding accounts receivable from PG&E on the bankruptcy filing date of January 29, 2019 was \$6.0 million. The Company currently expects to collect substantially all of the pre-bankruptcy accounts receivable from PG&E. However, due to the risks and uncertainties inherent in the bankruptcy process, the amount ultimately collected could differ from the Company’s current expectation. The Company continues to do work for PG&E post-bankruptcy filing and expects to be paid for this work in the ordinary course of business. Under the United States Bankruptcy code, PG&E is required to pay all post-bankruptcy expenses in the normal course of business. If they do not do so, the Company is eligible to have the post-bankruptcy obligation categorized as an administrative expense entitled to priority over most pre-bankruptcy creditors.

## Note 10: Segment Reporting

The Company has two reportable operating segments based on two primary areas of service. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and Health segment provides services in the area of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments but does not review total assets in evaluating segment performance and capital allocation.



Segment information for the three months ended March 29, 2019 and March 30, 2018 follows:

Revenues

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Engineering and Other Scientific	\$ 80,254	\$ 77,047
Environmental and Health	18,777	19,410
Total revenues	\$ 99,031	\$ 96,457

Operating Income

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Engineering and Other Scientific	\$ 25,974	\$ 25,913
Environmental and Health	6,196	6,624
Total segment operating income	32,170	32,537
Corporate operating expense	(16,416 )	(10,939 )
Total operating income	\$ 15,754	\$ 21,598

Capital Expenditures

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Engineering and Other Scientific	\$ 1,778	\$ 813
Environmental and Health	43	51
Total segment capital expenditures	1,821	864
Corporate capital expenditures	4,520	5,946
Total capital expenditures	\$ 6,341	\$ 6,810

Depreciation and Amortization

(In thousands)	Three Months Ended	
	March 29, 2019	March 30, 2018
Engineering and Other Scientific	\$ 1,121	\$ 1,095
Environmental and Health	45	39
Total segment depreciation and amortization	1,166	1,134
Corporate depreciation and amortization	424	421
Total depreciation and amortization	\$ 1,590	\$ 1,555

No single client comprised more than 10% of the Company's revenues during the three months ended March 29, 2019. One client comprised 16% of the Company's revenues during the three months ended March 30, 2018. No other single client comprised more than 10% of the Company's revenues during the three months ended March 30, 2018. One client comprised 13% of the Company's accounts receivable at March 29, 2019. No single client comprised more than 10% of the Company's accounts receivable at December 28, 2018.

## Note 11: Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current operating lease liabilities, and long-term operating lease liabilities in the Company's condensed consolidated balance sheet. The Company does not have any finance leases as of March 29, 2019.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statement of cash flows.



Edgar Filing: EXPONENT INC - Form 10-Q

The Company leases office, laboratory, and storage space in 13 states and the District of Columbia, as well as in Germany, China, Hong Kong, Singapore, Switzerland and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging between one and ten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain.

The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the state of Arizona under a 30-year lease agreement that expires in January of 2028 and has options to renew for two fifteen-year periods. As of March 29, 2019, the Company has determined that exercise of the renewal options is not reasonably certain and thus the extension is not included in the lease term.

The Company's equipment leases are included in the ROU asset and liability balances but are not material.

The Company leases excess space in its Silicon Valley facility. Rental income of \$741,000 was included in other income for the three months ended March 29, 2019.

The components of lease expense included in other operating expenses on the condensed consolidated statement of income were as follows:

	<b>Three Months Ended</b>
(In thousands)	<b>March 29, 2019</b>
Operating lease cost	\$ 1,870
Variable lease cost	\$ 380
Short-term lease cost	\$ 95

Supplemental cash flow information related to operating leases was as follows:

	<b>Three Months Ended</b>
(In thousands)	<b>March 29, 2019</b>
Cash paid for amounts included in the measurement of lease liabilities:	\$ 2,534

Supplemental balance sheet information related to operating leases was as follows:

**Three Months Ended**

**March 29, 2019**

Weighted Average Remaining Lease Term	5.6 years	
Weighted Average Discount Rate	4.5	%

- 18 -

Maturities of operating lease liabilities as of March 29, 2019:

(In thousands)	Operating Leases
2019 (excluding three months ended March 29, 2019)	\$ 4,700
2020	6,001
2021	4,950
2022	3,894
2023	2,601
2024	1,693
2025	1,491
2026	1,507
2027	1,466
Total lease payments	\$ 28,303
Less imputed interest	(3,982 )
Total lease liability	\$ 24,321

#### **Note 12: Contingencies**

The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.

- 19 -

## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 28, 2018, which are contained in our fiscal 2018 Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission on February 22, 2019 (our “2018 Annual Report”).

### **Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in this Quarterly Report under the heading “Risk Factors” and elsewhere in this report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. Due to such uncertainties and risks, you are warned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company does not intend to release publicly any updates or revisions to any such forward-looking statements.

### **Business Overview**

Exponent, Inc. is an engineering and scientific consulting firm that provides solutions to complex problems. Our multidisciplinary team of scientists, engineers and business consultants brings together more than 90 different technical disciplines to solve complicated issues facing industry and business today. Our services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to

products, people, property and impending litigation.

## **CRITICAL ACCOUNTING ESTIMATES**

There have been no significant changes in our critical accounting estimates during the three months ended March 29, 2019, as compared to the critical accounting estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 28, 2018.

## **RESULTS OF CONSOLIDATED OPERATIONS**

### **Executive Summary**

Revenues for the first quarter of 2019 increased 3% to \$99,031,000 as compared to \$96,457,000 during the same period last year. Revenues before reimbursements for the first quarter of 2019 increased 3% to \$93,401,000 as compared to \$90,684,000 during the same period last year. We experienced strong demand for our consulting services from a diverse set of clients for both proactive and reactive projects. During the first quarter of 2019, we deployed our interdisciplinary teams across multiple industry domains, allowing us to address the complex problems associated with integrated technologies. We leveraged the success of our large user study led by our human factors practice, and expanded our reach across new use cases as our clients look to unlock the power of data to inform artificial intelligence systems. Our expertise in battery technologies continues to be a source of strength as we expand into mobility devices. We also experienced increased demand for integrity management consulting related to electrical infrastructure, and engineering and construction management expertise on large international capital projects.

- 20 -

During the first quarter of 2019 we had strong growth in our human factors, materials & corrosion engineering, thermal sciences, structural engineering, construction consulting, and chemical regulation and food safety practices. During the first quarter of 2018, we worked on a large human factors assessment for a client in the consumer products industry. This project represented approximately 8% of our revenues before reimbursements in the first quarter of 2018. We completed this project during the third quarter of 2018. While we do not anticipate another project of this scale, we expanded our human factors practice during the first quarter of 2019 and are currently engaged with a variety of clients in the consumer products industry.

Net income increased 12% to \$22,712,000 during the first quarter of 2019 as compared to \$20,340,000 during the same period last year. Diluted earnings per share increased to \$0.42 per share as compared to \$0.38 in the same period last year. The increase in net income and diluted earnings per share was primarily due to a decrease in our effective tax rate. The decrease in the effective tax rate was due to an increase in the excess tax benefit associated with stock-based awards. The excess tax benefit associated with stock-based awards increased to \$5,670,000 during the first quarter of 2019 as compared to \$3,906,000 during the same period last year.

We remain focused on selectively adding top talent and developing the skills necessary to expand our market position and providing clients with in-depth scientific research and analysis to determine what happened and how to prevent failures or exposures in the future. We also remain focused on capitalizing on emerging growth areas, managing other operating expenses, generating cash from operations, maintaining a strong balance sheet and undertaking activities such as share repurchases and dividends to enhance shareholder value.

### Overview of the Three Months Ended March 29, 2019

During the first quarter of 2019 and 2018, billable hours were 329,000. Our utilization decreased to 72% during the first quarter of 2019 as compared to 77% during the same period last year. Technical full-time equivalent employees increased 7% to 883 during the first quarter of 2019 as compared to 825 during the same period last year. We continue to selectively hire key talent to expand our capabilities.

### Three Months Ended March 29, 2019 compared to Three Months Ended March 30, 2018

#### Revenues

(in thousands, except percentages)	Three Months Ended		Percent Change
	March 29, 2018	March 30, 2018	

**2019**

Engineering and Other Scientific	\$ 80,254		\$ 77,047		4.2	%
Percentage of total revenues	81.0	%	79.9	%		
Environmental and Health	18,777		19,410		(3.3	)%
Percentage of total revenues	19.0	%	20.1	%		
Total revenues	\$ 99,031		\$ 96,457		2.7	